ASSESSING THE LEADER TRIAL: UNDERSTANDING MYOCARDIAL INFARCTION SUBTYPES IN TYPE 2 DIABETES MELLITUS PATIENTS AND THE BENEFICIAL IMPACT OF LIRAGLUTIDE THERAPY.
Background: Myocardial infarction (MI), often associated with diabetes mellitus (DM), lacks detailed subtype data. Liraglutide, administered to high-risk Type 2 DM individuals, reduced major CV events, including CV mortality, non-fatal MI, and non-fatal stroke, based on the LEADER trial (8,240 part...
Saved in:
| Main Author: | |
|---|---|
| Format: | Book |
| Published: |
Student's Journal of Health Research,
2023-12-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Internet
Connect to this object online.3rd Floor Main Library
| Call Number: |
A1234.567 |
|---|---|
| Copy 1 | Available |